FULC

Fulcrum Therapeutics, Inc.

NasdaqGMUSDEQUITY DELAYED

3.83

▼ 0.02 (0.56%)

MARKET · —

Price

Open

3.65

Prev close

3.85

Day high

3.90

Day low

3.78

Volume

1.51M

Market cap

—

P/E (TTM)

—

52W range

2.83 – 15.74

Trailing performance

Price return · vs SPY

Returnvs SPY

+2.41% +3.8%

+1.86% -1.9%

-41.88% -45.0%

-65.18% -76.2%

YTD

-66.14% -78.4%

-41.70% -61.7%

-6.13% -80.3%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

3.79

+0.99% from price

SMA 20

3.76

+1.83% from price

SMA 50

3.69

+3.69% from price

SMA 100

5.22

-26.68% from price

SMA 200

7.55

-49.26% from price

EMA 12

3.80

+0.67% from price

EMA 26

3.80

+0.87% from price

EMA 50

4.09

-6.35% from price

RSI (14)

51.7

Neutral

MACD (12,26,9)

0.01

Hist 0.03

ATR (14)

0.13

3.26% of price

Realised vol 30D

31.3%

Annualised

Bollinger upper

3.93

20, 2σ

Bollinger lower

3.59

20, 2σ

50 / 200 cross

Death

3.69 vs 7.55

Trend bias

Below 200

-49.26%

Risk profile

Daily returns · 1Y window

Beta vs SPY

0.81

Less volatile than market

Correlation to SPY

0.11

Largely independent

Realised vol 30D

31.3%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-78.5%

Peak to trough

Max drawdown 5Y

-92.7%

Peak to trough

ATR 14

0.13

3.26% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 3.83

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

FULC · links out to the publisher

Fulcrum and Slate Medicines sign merger agreement Pharmaceutical Technology · 4d ago Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies Exec Edge · 5d ago Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal MarketBeat · 5d ago Fulcrum Therapeutics, Slate Medicines to Combine in All-Stock Merger MT Newswires · 5d ago Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies GlobeNewswire · 5d ago Slate, Fulcrum to combine in reverse merger BioPharma Dive · 5d ago Fulcrum Therapeutics (FULC) Stock Sees Modest Fair Value Lift After Pociredir Exit Simply Wall St. · 18d ago Fulcrum Therapeutics (FULC) Stock Fair Value Moves Lower After Pociredir Exit Simply Wall St. · 56d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.